Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two ot... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$47.02 - 0.53
Stock chart for: PTLA.O.  Currently trading at $47.02 with a 52 week high of $67.10 and a 52 week low of $17.74.
12/15/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Portola Pharmaceuticals, Inc. at the Credit Suisse 26th Annual Healthcare Conference
Wednesday, November 8, 2017 8:40 a.m. MT
LocationScottsdale, AZ

Q3 2017 Portola Pharmaceuticals, Inc. Earnings Conference Call
Monday, November 6, 2017 1:30 p.m. PT